Serum Butyrylcholinesterase and Hepatic Steatosis in U.S. Adults: A Nationally Representative NHANES Study

The liver is a tireless chemical factory, filtering blood, storing energy, and manufacturing proteins essential for life. In recent years, doctors have grown increasingly concerned about a condition where this factory becomes clogged with fat, a problem now known as metabolic dysfunction-associated steatotic liver disease. This condition is not just about having a little extra fat; it is a sign that the body's metabolism is struggling, often linked to issues with blood sugar, blood pressure, and weight. While the disease is becoming more common, it is also notoriously difficult to catch early because it rarely causes pain or obvious symptoms until it has already caused serious damage. To find it, specialists usually rely on expensive machines that bounce sound waves off the liver to measure its fat content and stiffness, or they perform biopsies, which involve taking a tiny piece of tissue with a needle. These methods are accurate but are not available to everyone, leaving a vast number of people unaware they are at risk.

Researchers have long wondered if a simple blood test could help spot this problem earlier. One specific protein in the blood, produced by the liver, has drawn attention for decades. This protein, called butyrylcholinesterase, is usually measured to see how well the liver is working in people with severe, advanced disease, where levels typically drop. However, a different pattern has emerged in smaller studies: in people with milder metabolic issues, this protein sometimes appears in higher amounts. It was unclear whether this rise was just a side effect of being overweight or if it was a specific signal that the liver was accumulating fat. To answer this, a team of scientists turned to a massive, nationally representative survey of American adults, looking for a clear link between the levels of this protein and the actual amount of fat in the liver.

The researchers analyzed data from over 5,000 adults who had undergone a specific, non-invasive scan of their liver. This scan uses sound waves to measure two things: how much fat is stored in the liver and how stiff the liver tissue has become, which indicates scarring. They also measured the activity and concentration of the butyrylcholinesterase protein in the blood of every participant. By comparing these measurements, the team could see if people with higher levels of the protein in their blood also had more fat in their livers. They carefully adjusted their calculations to account for age, sex, race, income, smoking habits, and other health factors like body weight and blood sugar, ensuring that any connection they found was specific to the liver fat and not just a result of general poor health.

The results showed a clear and steady relationship. As the levels of the butyrylcholinesterase protein in the blood went up, the amount of fat in the liver also went up. The study found that for every standard increase in the protein's activity, the fat content in the liver rose significantly. This pattern held true whether the researchers looked at the protein's ability to perform a chemical reaction or simply how much of the protein was present in the blood. People with the highest levels of this protein were much more likely to have the condition where the liver is filled with fat, compared to those with the lowest levels. The connection remained strong even after the researchers accounted for obesity and diabetes, suggesting that the protein carries specific information about liver fat that goes beyond just being overweight.

However, the story changed when the researchers looked at liver scarring, or fibrosis. While high levels of the protein were linked to fatty livers, they were not linked to the liver becoming stiff or scarred. In fact, the study found no evidence that high levels of this protein predicted the development of significant fibrosis. This distinction is important because it suggests the protein is a marker for the early stage of fat accumulation rather than the later stage of tissue damage. The researchers also noted that this finding was consistent across different groups of people and held up even when they excluded those with viral hepatitis or used slightly different definitions for what counts as a fatty liver.

The study concludes that this blood protein acts as a potential signal for the presence of fat in the liver, offering a new, accessible way to identify people who might need further screening. It does not replace the need for specialized scans or biopsies, nor does it serve as a tool to measure liver scarring. Instead, it points to a biological link where the liver, in its effort to manage fat and energy, produces more of this specific protein. While the study cannot prove that the protein causes the fat or that the fat causes the protein, it establishes a reliable association that could help doctors identify at-risk individuals sooner. The findings suggest that a simple blood test, already part of many standard medical panels, could one day be used alongside other tools to catch metabolic liver disease before it progresses to more dangerous stages.